Myovant Sciences names new chief commercial officer
8 November 2018 -

Myovant Sciences Ltd (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for women's health and endocrine diseases, announced yesterday that it has named Kim Sablich as its new chief commercial officer.

Sablich was vice president of Primary Care Marketing in the United States for GlaxoSmithKline. Prior to that, she was vice president, Global Medicines Commercialisation in the United Kingdom, and before that, vice president, Vaccines Commercial Strategies. Before joining GSK, she spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organisation across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas. She has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products. She is currently a member of the board of directors of AllerGenis LLC.

She earned a BA from Denison University and an MBA from The Wharton School of the University of Pennsylvania.